Yuandong Biotech announced that the company recently received the “Notice of Acceptance” for approval and marketing approval for aminophenol oxycodone extended-release tablets issued by the State Drug Administration. The drug is a compound tablet containing oxycodone hydrochloride and acetaminophen. It has a quick-release layer and a slow-release layer design, which not only works quickly, but also maintains long-term analgesic effects. Aminophenol oxycodone sustained-release tablets were submitted for clinical application in July 2022 for the treatment of moderate to severe acute and chronic pain. A phase III clinical study report was recently obtained, showing that they have similar analgesic effects and safety within 48 hours. Currently, no products of the same type have been listed at home or abroad. The company is the first company in China to apply for a listing license and receive acceptance.

Yuandong Biotech announced that the company recently received the “Notice of Acceptance” for approval and marketing approval for aminophenol oxycodone extended-release tablets issued by the State Drug Administration. The drug is a compound tablet containing oxycodone hydrochloride and acetaminophen. It has a quick-release layer and a slow-release layer design, which not only works quickly, but also maintains long-term analgesic effects. Aminophenol oxycodone sustained-release tablets were submitted for clinical application in July 2022 for the treatment of moderate to severe acute and chronic pain. A phase III clinical study report was recently obtained, showing that they have similar analgesic effects and safety within 48 hours. Currently, no products of the same type have been listed at home or abroad. The company is the first company in China to apply for a listing license and receive acceptance.